In a nutshell This phase 2 clinical trial will test the effectiveness of merestinib in non-small cell lung cancer patients with a mutation in the MET protein. The primary outcome will be measured by the overall response to the treatment. This study is being conducted in Boston, Massachusetts. The details Merestinib is an inhibitor of the C-Met...
Read More
In a nutshell This study investigated whether chemotherapy after rectal surgery improves survival of rectal cancer patients. Researchers suggested that chemotherapy after rectal surgery is associated with improved survival. Some background Rectal cancer affects almost 40,000 people annually in the United States. Roughly 50% of these patients...
Read More
In a nutshell The authors aimed to determine guidelines for the treatment of relapsing, metastatic, and hormone-resistant prostate cancer. Some background Metastatic prostate cancer (advanced cancer) is cancer that has spread outside of the prostate to other organs of the body, despite treatment. Hormone therapy is the standard...
Read More
In a nutshell The authors looked at the relationship between heart failure and different treatments for Hodgkin Lymphoma. This study concluded that the risk of heart failure increased with increasing radiation doses and the use of chemotherapy containing anthracyclines (such as doxorubicin). Some background Hodgkin lymphoma (HL) has high 10-year...
Read More
In a nutshell This study is the second update of a review focusing on the effects of an intense follow-up for patients with colorectal cancer after treatment. Some background Patients with colorectal cancer who underwent surgery or adjuvant therapy (treatment following surgery) are followed for several years. However, multiple appointments and...
Read More
In a nutshell This study compared the survival outcomes of two different age groups of relapsed and refractory Hodgkin lymphoma patients. The authors concluded that co-morbidities, not age, reduced survival rates after stem-cell surgery. Some background Hodgkin lymphoma (HL) is a type of cancer of the lymph system. It is generally highly...
Read More
In a nutshell This study evaluated the effectiveness of brentuximab-vedotin therapy in relapsed- and refractory Hodgkin lymphoma patients. The authors concluded that the treatment was safe and effective. Some background Some Hodgkin lymphoma patients are either unresponsive to treatment (refractory disease), or relapse soon...
Read MoreIn a nutshell This study determined the impact of cancer-related fatigue on Hodgkin-Lymphoma patients and survivors. The authors concluded that fatigue particularly affected social integration. Some background Hodgkin-Lymphoma (HL) patients and survivors can experience persistent cancer-related fatigue. Reports of fatigue occur 2.5 to 3...
Read MoreIn a nutshell This study examined different treatment options for elderly men with localized prostate cancer. Researchers reported that radiation therapy with or without hormone therapy was associated with a significant survival benefit when compared to observation alone. Some background Localized prostate cancer refers to cancer that is confined...
Read More
In a nutshell This study assessed whether patients with relapsed- or refractory Hodgkin Lymphoma should be treated with radiation therapy. The authors concluded that radiation therapy was safe and prevented the return of the disease in certain patients. Some background Hodgkin lymphoma is a cancer of the lymph system. It is a...
Read More
In a nutshell This trial examined the effectiveness of bendamustine in patients with Hodgkin lymphoma that did not respond to treatment or returned after a period without disease. The authors found that this treatment was effective in this population. Some background About 30% of Hodgkin lymphoma patients will either not respond to treatment...
Read More
In a nutshell This trial examined the longer-term effectiveness of brentuximab vedotin (Adcetris) after stem cell transplant in patients with relapsed or refractory (did not respond to treatment) Hodgkin lymphoma. The authors concluded that patients who respond to brentuximab vedotin can achieve long-term disease control. Some background...
Read More
